Temozolomide with or without WSD0922-FU for EGFR-mutant glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a new drug, WSD0922-FU, to standard chemotherapy (temozolomide) works better than temozolomide alone for a specific type of glioblastoma that has an EGFR mutation. It is for patients who have completed radiation and temozolomide together but haven't started maintenance temozolomide yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a glioblastoma that does not have an IDH mutation and does have an EGFR mutation (a change in a gene that helps tumors grow).
- You finished radiation therapy with temozolomide and recovered from side effects, but you have not started the next phase of temozolomide treatment.
- You can perform daily activities with little or no help (ECOG score 0-2).
- Your blood counts, kidney function, and liver function tests are within safe ranges.
- You are willing to avoid sunlight and use sun protection during the study and for 2 weeks after your last dose of WSD0922-FU.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
This trial tests if adding a wafer (Cerebraca) placed in the brain during surgery to standard chemotherapy (temozolomide) works better than chemotherapy alone for people whose glioblastoma has come back after first treatment.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.